<DOC>
	<DOCNO>NCT00000547</DOCNO>
	<brief_summary>To determine chronic administration enalapril , inhibitor angiotensin convert enzyme ( ACE ) , reduce progression cardiac dysfunction pediatric oncology patient receive anthracyclines , currently digoxin , diuretic , vasodilator heart failure .</brief_summary>
	<brief_title>Enalapril After Anthracycline Cardiotoxicity</brief_title>
	<detailed_description>BACKGROUND : Pediatric oncology patient treat anthracycline therapy part chemotherapeutic regimen often subsequently develop leave ventricular failure . The optimal medical management know . This trial first provide comprehensive data well characterize population regard role afterload reduction use enalapril treat ventricular dysfunction anthracycline chemotherapy DESIGN NARRATIVE : Randomized , double-blind . Randomization stratify total anthracycline dose , follow-up time treatment , age time treatment . All patient receive following baseline test : Maximal Cardiac Index ( MCI ) cycle ergometry ; echocardiogram/Doppler determine leave ventricular end systolic wall stress ( ESWS ) ; gate nuclear angiography ( GNA ) determine leave ventricular ejection fraction ; Holter monitor 24 hour ECG monitoring . Patients randomize either enalapril placebo . Follow-up visit conduct ensure compliance screen side effect . MCI ESWS measure twice yearly , four test repeat conclusion trial , four five year treatment . The primary outcome variable rate decline MCI rate increase ESWS . Secondary outcome change leave ventricular ejection fraction incidence arrhythmia . A second aim study develop algorithm determine indication enalapril use study succeed show treatment effect . This required modeling probability cardiac dysfunction give patient characteristic treatment , treatment type , cardiac status treatment follow-up , development cost effectiveness medical decision making model test propose algorithm . The study completion date list record obtain `` Completed Date '' enter Query View Report System ( QVR ) .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<criteria>Boy girl pediatric oncology patient , least two year treatment , cardiac dysfunction , congestive heart failure , receive anthracyclines . Patients digoxin , diuretic , vasodilator heart failure .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2005</verification_date>
</DOC>